Loading
Singlera's PanSeer methylation test, run on stored blood from a Chinese cohort, flagged most people who went on to be diagnosed with one of five cancers within four years.
In the Taizhou Longitudinal Study, 123,115 healthy people gave plasma for storage and were followed for cancer. PanSeer, a circulating tumour DNA methylation test, was run on samples from 605 asymptomatic individuals, 191 of whom were later diagnosed with stomach, oesophageal, colorectal, lung or liver cancer within four years, plus 223 cancer patients and 200 tissues. It detected the five cancers in 88% (95% CI 80 to 93) of post-diagnosis patients at 96% specificity (93 to 98), and in 95% (89 to 98) of asymptomatic individuals later diagnosed; the authors state that future longitudinal studies are required to confirm this result.
An eye-catching result from a nested case-control analysis of stored samples; it has not been reproduced in a prospective screening study.
Shares Singlera Genomics, PanSeer, Multi-cancer early detection (MCED).
Shares Singlera Genomics, PanSeer, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Nature Communications, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/